CCL17 Antibody
Description
Therapeutic Targets and Mechanisms
CCL17 antibodies neutralize the chemokine’s interaction with its receptor CCR4, disrupting immune cell recruitment in disease contexts. Key therapeutic applications include:
Disease-Specific Roles
-
Viral myocarditis: CCL17 antibodies enhance interferon signaling by reducing regulatory T-cell infiltration, improving viral clearance .
-
Autoimmunity: Neutralization reduces eosinophil recruitment in atopic dermatitis and delays multiple sclerosis progression .
-
Cancer: High CCL17 expression correlates with tumor immune infiltration but variable clinical outcomes (e.g., improved prognosis in melanoma vs. tumor-promoting effects in thyroid cancer) .
Clinical and Diagnostic Applications
The antibody is used in:
-
Immunohistochemistry: Detects CCL17 in human colon, placenta, and cancer tissues (e.g., colon cancer) .
-
ELISA: Quantifies serum CCL17 levels for biomarker studies .
-
Flow cytometry: Analyzes CCL17-expressing immune cells in inflammatory exudates .
Key Research Challenges
-
Therapeutic Paradox: CCL17 inhibition may worsen outcomes in acute viral myocarditis by suppressing protective immune responses .
-
Tumor Microenvironment: Dual roles in promoting/suppressing immune evasion necessitate context-specific targeting .
-
CCR4 Cross-Talk: Antibodies must avoid interfering with beneficial CCR4 ligands like CCL22 .
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research suggests that TNF-alpha-induced CCL17 mRNA transcription in canine keratinocytes is positively regulated by p38 but negatively controlled by ERK. PMID: 20837364
- Studies indicate that interferon-gamma may suppress granulocyte-macrophage colony stimulating factor production from canine keratinocytes, although further research is needed to confirm this finding. PMID: 20860556
- Inflammatory cytokines are significant inducing factors for CCL17 production in the lesional skin of dogs with atopic dermatitis. PMID: 20022349
